Zanubrutinib (Brukinsa) displayed durable efficacy with a sustained progression-free survival (PFS) benefit in patients with relapsed/refractory chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), according to findings from the…
Zanubrutinib Demonstrates Long-Term Efficacy, Safety in Relapsed/Refractory CLL/SLL
